|Description||Nivolumab, marketed as Opdivo, is a humanized IgG4 anti-PD-1 monoclonal antibody used to treat cancer. Nivolumab works as a checkpoint inhibitor, blocking a signal that would have prevented activated T cells from attacking the cancer, thus allowing the immune system to clear the cancer.|
|Brife Description||Marketed as Opdivo; A humanized IgG4 anti-PD-1 monoclonal antibody used to treat cancer; FDA Approved|
|Sequence||Light Chain Sequence:
Heavy Chain Sequence:
|Synonyms||Opdivo; ONO-4538; BMS-936558; MDX1106|
|Current Developer||Bristol-Myers Squibb; Duke University Medical Center; Eli Lilly; Grupo Espanol Multidisciplinar de Melanoma; Incyte Corporation; Janssen Research & Development; Kyoto University; Kyowa Hakko Kirin; Medarex; National Cancer Institute (USA); Netherlands Cancer Institute; Ono Pharmaceutical; Seattle Genetics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Texas M. D. Anderson Cancer Center|
A humanized, immunoglobulin (Ig) G1 monoclonal antibody directed against human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune ...
Nivolumab, marketed as Opdivo, is a humanized IgG4 anti-PD-1 monoclonal antibody used to treat cancer. Nivolumab works as a checkpoint inhibitor, blocking a sig...
A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1)...
Tislelizumab is a humanized monoclonal antibody (MAb) that targets PD-1 to prevent it binding to PD-L1 and PD-L2. Tislelizumab is developed for the treatment of...
A fusion protein that contains the extracellular domain of PD-1 ligand 2 (B7-DC; PDCDILG2) and the Fc region of human immunoglobulin (Ig) G1. AMP-224 does not ...
Pembrolizumab (formerly MK-3475 and lambrolizumab, trade name Keytruda) is a humanized antibody used in cancer immunotherapy. It targets the programmed cell dea...